Standfirst

Aerospace structures, defence technology services and specialist thermal processing sit at very different points of the industrial cycle, yet Melrose Industries plc (LSE:MRO), QinetiQ Group plc (LSE:QQ.) and Bodycote plc (LSE:BOY) have each reported growth in 2026. This FTSE All-Share engineering sector watch sets out what their latest verified results show, and where the risks lie for the rest of the year.

Introduction – Sector Outlook for September 2026

UK engineers are contending with a familiar mix of steady-but-unspectacular Demand and a monetary backdrop that has stopped tightening without yet easing. The Bank of England held its Base Rate at 3.75% on 30 July 2026, with the Monetary Policy Committee split 6–3 as three members pushed for a rise to 4% amid firmer inflation. UK CPI rose to 2.9% in July 2026, up from 2.6% in June, and the Bank was widely expected to hold again at its 17 September meeting. The S&P Global/CIPS UK Manufacturing PMI stood at 51.7 in August 2026, down slightly from 51.9 in July but still signalling expansion for a fifth consecutive month, even as growth in output and new orders eased to its weakest pace since April. Manufacturing employment rose at its fastest pace in two years and Business confidence reached a six-month high, with Investment goods — the category that includes much of aerospace and industrial engineering — recording the steepest growth in both production and new orders.

This sector watch groups together three companies whose products and end-markets differ substantially, unified by a shared identity as UK-listed engineering businesses rather than a single market. Melrose Industries is a pure-play aerospace structures and engine-components group, trading through its GKN Aerospace brand, following the 2023 demerger that separated its automotive operations into the standalone Dowlais Group. QinetiQ Group is better described as a defence and security technology and research-services company than a conventional manufacturer, serving the UK Ministry of Defence, the US Department of Defense and allied governments. Bodycote is a specialist engineering-services group — the world's largest independent provider of thermal processing, the heat treatment, hot isostatic pressing and surface technology that manufacturers rely on to strengthen and finish metal components across aerospace, automotive, energy and general industrial markets.

Despite their differences, common threads run through all three this year: order books at or near record levels, aerospace build-rate recovery feeding through to results, and government or allied defence spending providing Revenue visibility unusual for cyclical industrials. What differs sharply is exposure to broader industrial and automotive capital-spending cycles — a far bigger swing Factor for Bodycote than for Melrose or QinetiQ — and the extent to which a single reporting period can be distorted by one-off events, as Melrose shareholders were reminded in 2026.

The sections that follow set out the most recently verified results for each company, a period-labelled comparison, the sector drivers likely to matter through the rest of 2026, and a balanced assessment of the risks — without recommending that investors buy, sell or hold any of the three.

Melrose Industries plc (LSE:MRO)

Melrose Industries has operated as a focused aerospace engineering group since demerging its automotive division as Dowlais Group in 2023, trading through the GKN Aerospace Brand it acquired in 2018. The business is organised into two divisions: Engines, which makes structural and rotating components for large civil and military aero-engines supplied to manufacturers including Rolls-Royce, GE Aerospace, Pratt & Whitney and Safran; and Airframes, which produces metallic and composite structures — wings, fuselage sections and engine nacelles — for aircraft including the Airbus A320 and A350 families and Boeing programmes, alongside defence platforms.

Melrose reported its 2026 half-year results, for the six months to 30 June 2026, on 31 July 2026. Revenue rose 10% to £1,873 million (H1 2025: £1,720 million), and adjusted operating profit increased 16% to £347 million, lifting the adjusted Operating Margin to 18.5% from 18.0%. Statutory operating profit fell to £154 million from £441 million a year earlier, a comparison affected by the scale of exceptional items and prior-year gains rather than by underlying trading. Adjusted Diluted Earnings per Share grew 22% to 17.7 pence, while statutory diluted EPS fell to 6.0 pence from 22.2 pence. Free Cash Flow improved sharply to a £13 million inflow, from a £54 million outflow in H1 2025, though net Debt rose to £1,530 million from £1,407 million at the end of December 2025, equivalent to 1.8 times EBITDA.

By division, Engines revenue grew 19% to £896 million with adjusted operating profit up 21% to £303 million, a 33.8% margin. Airframes revenue rose a more modest 4% to £977 million, with adjusted operating profit down 1% to £62 million and margin easing to 6.3% from 6.7% — though management said the underlying margin, excluding a chemical-tank incident at its Garden Grove, California Facility in May 2026, would have been 7.2%, up 50 basis points. That incident reduced H1 revenue by £16 million and adjusted operating profit by £9 million, generated £13 million of exceptional costs with a further £25 million to £30 million expected in H2, and left the site at around half capacity with an estimated ongoing impact of roughly £6 million a month. The board consequently paused the £175 million 2026 buyback programme — of which £70 million had been spent — pending clarification of the incident's financial impact; subsequent statements have pointed to a phased production restart and progress on an Insurance Claims programme.

Excluding the Garden Grove impact, guidance for full-year 2026 is for revenue of £3,750 million to £3,950 million, adjusted operating profit of £700 million to £750 million (around 19% margin at the midpoint), free cash flow of £150 million to £200 million after interest and tax, and variable consideration of £340 million to £380 million. The board declared an Interim Dividend of 2.7 pence per share, up 13% on 2.4 pence a year earlier. Market data as at 14 September 2026 show the shares at 476.0p, valuing the group at approximately £5.93 billion, on a trailing price-to-earnings multiple of about 37.3 times trailing-twelve-month earnings per share of 12.75 pence, and a Dividend Yield near 1.6%; the dataset records a consensus analyst rating of Buy.

Catalysts to watch include the pace of the Garden Grove restart, resumption of the paused buyback, further clarity on insurance recoveries, and continued civil-aerospace build-rate momentum at Airbus and Boeing. The principal risks are a slower-than-expected Garden Grove recovery, further exceptional costs beyond current guidance, rising net debt and leverage, and Airframes’ structurally thinner margins relative to Engines, which leave overall group profitability more exposed to any softening in build rates.

QinetiQ Group plc (LSE:QQ.)

QinetiQ is a UK-headquartered defence and security technology company rather than a conventional industrial engineer, providing research, testing, evaluation and engineering services to the UK Ministry of Defence, the US Department of Defense and allied governments. Its UK business operates the Long Term Partnering Agreement (LTPA), under which QinetiQ manages a network of MOD test-and-evaluation ranges, while its Global Products arm — including the Roke technology consultancy — develops robotics, cyber, electronic-warfare and sensing technology for defence and security customers.

QinetiQ's full-year results for the year ended 31 March 2026 were published in June 2026. Group revenue was broadly flat at £1,923 million, with organic growth of 1.3% driven by a strong UK performance offsetting softer conditions elsewhere. Underlying operating profit rose 18% to £218 million, lifting the underlying operating margin to 11.3% — up 170 basis points and back within the group's target range. Statutory operating profit was £170 million, a marked recovery from a statutory operating loss of £91 million in FY2024/25. Basic Earnings Per Share rose 21% to 31.5 pence, free cash flow increased 41% to £159 million, and net debt stood at £159 million, a modest 0.5 times leverage.

Order intake reached a record £3,573 million, up 83%, including a £1,543 million extension to the LTPA that runs to 2033, alongside a separate £205 million five-year contract for Typhoon engineering support services. The resulting order Backlog of £4.8 billion — a book-to-bill ratio of 1.14 times excluding the LTPA extension — gives the group unusually strong revenue visibility for a technology-services business. Chief executive Steve Wadey described the year as delivering 'a resilient performance in more challenging markets,' citing 'clear visibility of sustainable growth.'

The board declared a full-year dividend of 11.00 pence per share, up 24%, and introduced a new payout target of 35% to 40% of underlying earnings per share, alongside a £200 million share buyback extended through to FY2029 (around £100 million a year). For FY2026/27, management guided to revenue growth of 3% to 5%, an underlying operating margin of 11.0% to 11.5%, underlying EPS growth of 8% to 10%, and cumulative free cash flow of more than £550 million across FY2027 to FY2029. Market data as at 14 September 2026 put the shares at 472.4p, a Market Capitalisation of roughly £2.41 billion, a trailing price-to-earnings ratio of 23.9 times trailing-twelve-month earnings per share of 19.79 pence, and a dividend yield of 2.33%; the supplied dataset’s consensus rating is Buy.

Catalysts include conversion of the record £4.8 billion backlog into billed revenue, further contract awards building on the LTPA extension, and progress toward the FY2029 free-cash-flow target. The main risks are QinetiQ's dependence on UK and US government defence budgets and procurement timetables, execution risk on long-cycle technology programmes, and the possibility — evident in FY2024/25's statutory operating loss — that exceptional items in its more commercially exposed Global Products business can weigh on reported profitability even when underlying trading is improving.

Bodycote plc (LSE:BOY)

Bodycote is the world's largest provider of thermal processing services, operating from more than 150 facilities across around 20 countries. Its core services — heat treatment, hot isostatic pressing (HIP) and surface technology — improve the strength and durability of metal and composite components, used across aerospace, automotive, energy, general industrial, medical and transportation manufacturing. Rather than making finished products, Bodycote processes components on behalf of manufacturers under an asset-heavy, service-based model, with long-standing customer relationships and accreditation barriers to entry, particularly in aerospace.

In results for the six months to 30 June 2026, Bodycote reported revenue of £381.2 million, up 3.3% on H1 2025's £369.0 million, with organic growth of 6.5% (the difference reflecting currency translation and site disposals). Adjusted operating profit rose 10.7% to £61.0 million, lifting the adjusted operating margin to 16.0% from 14.9%. Statutory operating profit also grew 10.7%, to £45.6 million, and statutory profit for the period rose to £31.2 million from £28.0 million. Adjusted EPS increased 18.3% to 25.2 pence, and statutory EPS rose 16.8% to 18.1 pence. Free cash flow was £14.5 million, down from £18.0 million, while net debt (excluding Lease liabilities) increased to £135.2 million from £104.8 million at the end of December 2025.

The margin improvement owes much to Bodycote's self-help 'Optimise' programme, a multi-year initiative to close or consolidate underperforming sites: 27 of a planned 31 site closures and consolidations were complete by the half-year, with management exploring further scope for expansion in automotive and industrial facilities. The group also completed the Acquisition of Spectrum Thermal Processing LLC in January 2026 for approximately £6 million, adding North American aerospace heat-treatment capacity.

The board declared an interim dividend of 7.2 pence per share, up 4.3% on 6.9 pence, and reiterated unchanged full-year 2026 guidance for organic revenue growth and further margin improvement supported by Optimise benefits, while acknowledging awareness of geopolitical headwinds affecting parts of its industrial and automotive customer base. Market data as at 14 September 2026 put the shares at 940.0p, a market capitalisation of approximately £1.59 billion, a trailing price-to-earnings ratio of 28.0 times trailing-twelve-month earnings per share of 33.57 pence, and a dividend yield of 2.45%; the supplied dataset records a consensus rating of Buy.

Catalysts include further Optimise-driven margin gains, continued aerospace build-rate recovery at Airbus and Boeing — Bodycote processes components across both OEMs' Supply chains without being directly exposed to either Balance Sheet — and further bolt-on acquisitions such as Spectrum. The principal risks are Bodycote's meaningful exposure to the automotive and general-industrial capital-spending cycle, a considerably more cyclical end-market than aerospace, rising net debt, and the sensitivity of an energy-intensive processing model to energy costs, alongside currency translation given the group's broad international footprint.

How the Three FTSE All-Share Stocks Compare

Read together, the three occupy different places on the engineering spectrum. QinetiQ offers the clearest multi-year revenue visibility, underpinned by its £4.8 billion order backlog and long-term government contracts. Bodycote combines steady, less glamorous organic growth with a self-help margin story through Optimise, at the most modest valuation of the three. Melrose delivers the fastest Underlying Profit growth but is currently working through a one-off operational setback at Garden Grove whose full financial resolution remains pending.

What Could Drive the Engineering Sector Through the Rest of 2026?

For Melrose, the dominant near-term driver is resolution of the Garden Grove incident: the pace of the site's return to full capacity, second-half exceptional costs against the guided £25 million to £30 million range, and progress on insurance recoveries will determine whether the paused buyback resumes before year-end. Longer term, civil-aerospace build rates and mix shift toward higher-margin Engines work remain the key swing factors for underlying profitability.

For QinetiQ, the principal driver is converting its record order backlog and LTPA extension into billed revenue at target margins, alongside further contract wins of the scale seen in FY2025/26. UK and allied defence budgets — still supported by NATO members' commitments to higher spending, even where pace varies by country — provide a broadly favourable backdrop, though procurement timetables can slip for political or budgetary reasons.

For Bodycote, the swing factor is less geopolitical and more industrial: the health of automotive and general manufacturing Capital spending across Europe and North America, set against more resilient aerospace processing work benefiting from the same build-rate recovery lifting Melrose. Continued Optimise savings and disciplined bolt-on M&A give Bodycote some control over its own margin trajectory even where end-market demand is mixed. Across all three, a stable UK interest-rate path would ease financing costs without directly determining demand, which remains driven by aerospace and defence cycles rather than domestic monetary policy.

Potential Catalysts to Watch

QinetiQ typically reports interim results for the six months to 30 September in mid-November; the figures will be the first test of its 3% to 5% revenue-growth guidance. Melrose should update on Garden Grove's recovery ahead of full-year 2026 results in early 2027. Bodycote's full-year 2026 results, expected in Q1 2027, will show whether the final Optimise closures completed and margin guidance was met. The Bank of England's 17 September 2026 decision and subsequent PMI readings will shape sentiment toward UK industrials; investors should treat confirmed contracts, dividends and results as verified events, and forecasts beyond company guidance as separate, non-guaranteed estimates.

Key Risks Investors Should Consider

Melrose's most immediate risk is that the Garden Grove incident's financial impact proves larger or more prolonged than currently guided; the buyback pause itself signals management's own uncertainty about the eventual cost. Airframes' structurally thinner margins than Engines also leave group profitability sensitive to programme mix, and net debt of £1,530 million (1.8 times EBITDA) reduces headroom should trading deteriorate.

QinetiQ's risks centre on reliance on government customers: UK and US defence budgets, while currently supportive, are subject to political cycles and fiscal pressure, and complex, long-cycle programmes carry execution risk that can produce exceptional charges of the kind behind FY2024/25's statutory operating loss even as underlying trading improves. A slowdown in order conversion relative to the record £3,573 million FY2025/26 intake would also weigh on the growth narrative.

Bodycote is the most exposed of the three to a genuine industrial downturn: automotive and general manufacturing capital spending can fall sharply in a recession, and while aerospace processing has offset this in 2026, that balance could shift. Rising net debt, energy-cost sensitivity, and currency translation given its broad footprint are additional considerations. Across all three, a sharper UK or global slowdown, Inflation keeping rates higher for longer, and disruption in specialised aerospace or defence supply chains represent shared, sector-wide risks.

Conclusion

September 2026 finds Melrose Industries, QinetiQ and Bodycote at different stages of their own stories rather than following a single sector script. QinetiQ combines a record backlog with the steadiest earnings visibility and a newly generous dividend policy. Bodycote offers a lower-multiple, self-help margin-improvement story that is more exposed to the broader industrial cycle than the other two. Melrose delivers the fastest underlying profit growth of the three but is still working through the financial resolution of an unplanned incident whose full cost will not be known for some months.

None of the three should be read as a proxy for UK engineering as a whole: their end-markets, customer concentration and cyclicality differ substantially, and the developments most worth monitoring — Garden Grove’s recovery, backlog conversion at QinetiQ, and Optimise completion at Bodycote — are company-specific rather than macroeconomic.